Navigation Links
Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
Date:11/1/2007

MISSISSAUGA, ON, Nov. 1 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that Vasogen's management will present at the following investor conferences in November:

Acumen BioFin Rodman & Renshaw 9th Annual Global Healthcare Conference,

The New York Palace Hotel

Tuesday, November 6, 2007 at 11:40 a.m. (ET)

JMP Securities Healthcare Focus Conference, Four Seasons Hotel, Boston

Tuesday, November 13, 2007 at 2:00 p.m. (ET)

Lazard Capital Markets Fourth Annual Healthcare Conference,

The New York Palace Hotel

Tuesday, November 27, 2007 at 1:00 p.m. (ET)

The presentations will be webcast live and available for replay from Vasogen's website, http://www.vasogen.com.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Certain statements contained in this press release, the upcoming presentations and webcasts, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. New Sonic Foundry search engine finds words, phrases in video presentations
3. Sonic Foundry creates search engine for 7,000 expert video presentations
4. InvestMidWest calls for business presentations
5. BxVideo designs Web hosting service for Sonic Foundry media presentations
6. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
7. The TripleMaster PCR System for three different amplifications
8. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
9. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
10. Three finalists named for UW-Madison CIO
11. Three state businesses receive technology grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, ... the National Stroke Association during National Stroke Awareness Month in May. An ... pages throughout the month. CereScan will donate $1 up to a maximum ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its annual month-long ... grow on nerves throughout the body. It affects 1 in 3,000 people of all ... during the month of May, as well as online activities, Neurofibromatosis Awareness Month and ...
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... ... 2016 , ... Flagship Biosciences, the leader in tissue ... of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, in ... Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 through ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):